These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 29307234)

  • 1. Reprogramming T-cells for adoptive immunotherapy of ovarian cancer.
    Genta S; Ghisoni E; Giannone G; Mittica G; Valabrega G
    Expert Opin Biol Ther; 2018 Apr; 18(4):359-367. PubMed ID: 29307234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer.
    Owens GL; Sheard VE; Kalaitsidou M; Blount D; Lad Y; Cheadle EJ; Edmondson RJ; Kooner G; Gilham DE; Harrop R
    J Immunother; 2018 Apr; 41(3):130-140. PubMed ID: 29239915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
    Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospects of chimeric antigen receptor T cell therapy in ovarian cancer.
    Jindal V; Arora E; Gupta S; Lal A; Masab M; Potdar R
    Med Oncol; 2018 Apr; 35(5):70. PubMed ID: 29651744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiparameter comparative analysis reveals differential impacts of various cytokines on CART cell phenotype and function ex vivo and in vivo.
    Xu XJ; Song DG; Poussin M; Ye Q; Sharma P; Rodríguez-García A; Tang YM; Powell DJ
    Oncotarget; 2016 Dec; 7(50):82354-82368. PubMed ID: 27409425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse.
    Cummins KD; Gill S
    Leuk Lymphoma; 2018 Jul; 59(7):1539-1553. PubMed ID: 28901790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies to genetically engineer T cells for cancer immunotherapy.
    Spear TT; Nagato K; Nishimura MI
    Cancer Immunol Immunother; 2016 Jun; 65(6):631-49. PubMed ID: 27138532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
    Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
    Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
    [No Abstract]   [Full Text] [Related]  

  • 9. Adoptive immunotherapy against ovarian cancer.
    Mittica G; Capellero S; Genta S; Cagnazzo C; Aglietta M; Sangiolo D; Valabrega G
    J Ovarian Res; 2016 May; 9(1):30. PubMed ID: 27188274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer.
    Koneru M; O'Cearbhaill R; Pendharkar S; Spriggs DR; Brentjens RJ
    J Transl Med; 2015 Mar; 13():102. PubMed ID: 25890361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Follicle-Stimulating Hormone Receptor as a Target in the Redirected T-cell Therapy for Cancer.
    Urbanska K; Stashwick C; Poussin M; Powell DJ
    Cancer Immunol Res; 2015 Oct; 3(10):1130-7. PubMed ID: 26112923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic Chemoimmunotherapy of Epithelial Ovarian Cancer Using ErbB-Retargeted T Cells Combined with Carboplatin.
    Parente-Pereira AC; Whilding LM; Brewig N; van der Stegen SJ; Davies DM; Wilkie S; van Schalkwyk MC; Ghaem-Maghami S; Maher J
    J Immunol; 2013 Sep; 191(5):2437-45. PubMed ID: 23898037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
    Singh N; Frey NV; Grupp SA; Maude SL
    Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploiting natural killer group 2D receptors for CAR T-cell therapy.
    Demoulin B; Cook WJ; Murad J; Graber DJ; Sentman ML; Lonez C; Gilham DE; Sentman CL; Agaugue S
    Future Oncol; 2017 Aug; 13(18):1593-1605. PubMed ID: 28613086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
    Zhang E; Gu J; Xu H
    Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possible Compartmental Cytokine Release Syndrome in a Patient With Recurrent Ovarian Cancer After Treatment With Mesothelin-targeted CAR-T Cells.
    Tanyi JL; Stashwick C; Plesa G; Morgan MA; Porter D; Maus MV; June CH
    J Immunother; 2017 Apr; 40(3):104-107. PubMed ID: 28234665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CARTs for Solid Tumors: Feasible or Infeasible?
    Li W; Song X; Jin Y; Li F; Yu H; Cao C; Jiang Q
    Oncol Res Treat; 2017; 40(9):540-546. PubMed ID: 28813706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.
    Walker AJ; Majzner RG; Zhang L; Wanhainen K; Long AH; Nguyen SM; Lopomo P; Vigny M; Fry TJ; Orentas RJ; Mackall CL
    Mol Ther; 2017 Sep; 25(9):2189-2201. PubMed ID: 28676342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T.
    Yoon DH; Osborn MJ; Tolar J; Kim CJ
    Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29364163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.